SERENA-6: A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor
ENROLLING
Trial ID:
NCT04964934 Protocol # :
21-518
Phase
III
Disease Sites
Breast
Principal Investigator
Mayer, Erica, L
Site Research Nurses
Brule, Maurice, N.
Campbell, Margaret
Caradonna, Lisa
Cung, Connie
Ficociello, Samantha
Fleming, Norah, Michelle
Freeman, Stefani, Danielle
Gentile, Alissa
Ginter, Lindsey
Hixon, Nicole, R.
Holdsworth, Clay, Houghton
Houghton, Nicole
Jeon, Maryangel, H.
Kasparian, Elizabeth
Kosinski, Michelle
Kuhlman, Rachel
Miles, Brandy
Orechia, Meghan
Patel, Nikita
Quinn, Caroline
Roche, Kathleen, A.
Rutter, Morgan
Trial Description
Call 877-DF-TRIAL (877-338-7425) to learn more about this clinical trial, protocol #21-518
21-518